Rigel Pharmaceuticals (RIGL)

$21.49 +0.52 (2.48%)
Market Cap 384.07M
Revenue (ttm) 179.28M
Net Income (ttm) 17.49M
EPS (ttm) N/A
PE Ratio 10.13
Forward PE 9.31
Profit Margin 9.76%
Debt to Equity Ratio 2.42
Volume 182,300
Avg Vol 217,180
Day's Range N/A - N/A
Shares Out 17.87M
Stochastic %K 89%
Beta 1.29
Analysts Sell
Price Target $33.74

Latest News on RIGL

Rigel to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:05 AM EDT - 12 days ago

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 22, 2025, 5:20 PM EDT - 17 days ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 7, 2025, 6:16 PM EDT - 4 weeks ago

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:13 PM EDT - 4 weeks ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:01 PM EDT - 4 weeks ago

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Apr 29, 2025, 8:05 AM EDT - 5 weeks ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Apr 4, 2025, 3:31 PM EDT - 2 months ago

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Apr 4, 2025, 8:05 AM EDT - 2 months ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 27, 2025, 8:05 AM EDT - 2 months ago

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Appoints Mark W. Frohlich, M.D.

Mar 10, 2025, 8:05 AM EDT - 3 months ago

Rigel Appoints Mark W. Frohlich, M.D.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:29 PM EST - 3 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 4:01 PM EST - 3 months ago

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 8:05 AM EST - 3 months ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 22, 2025, 8:05 AM EST - 4 months ago

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Provides Business Update and 2025 Outlook

Jan 13, 2025, 8:05 AM EST - 5 months ago

Rigel Provides Business Update and 2025 Outlook

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 9, 2025, 8:05 AM EST - 5 months ago

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:05 AM EST - 5 months ago

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Dec 30, 2024, 8:30 AM EST - 5 months ago

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Dec 9, 2024, 12:02 PM EST - 6 months ago

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Dec 2, 2024, 8:05 AM EST - 6 months ago

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:05 AM EST - 7 months ago

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:25 PM EST - 7 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:01 PM EST - 7 months ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 7 months ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Oct 31, 2024, 8:05 AM EDT - 7 months ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Oct 24, 2024, 4:35 PM EDT - 8 months ago

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Oct 16, 2024, 10:00 AM EDT - 8 months ago

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Rigel Pharmaceuticals: Looking For More Growth

Oct 10, 2024, 7:32 AM EDT - 8 months ago

Rigel Pharmaceuticals: Looking For More Growth

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 9, 2024, 8:42 PM EDT - 8 months ago

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Oct 4, 2024, 8:05 AM EDT - 8 months ago

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:05 AM EDT - 9 months ago

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Sep 5, 2024, 7:30 AM EDT - 9 months ago

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Sep 3, 2024, 8:00 AM EDT - 9 months ago

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Rigel to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 8:05 AM EDT - 10 months ago

Rigel to Participate in Upcoming September Investor Conferences

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 2:12 PM EDT - 10 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 4:01 PM EDT - 10 months ago

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Jul 30, 2024, 8:05 AM EDT - 11 months ago

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24, 2024, 3:06 AM EDT - 11 months ago

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Jun 27, 2024, 10:00 AM EDT - 1 year ago

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Rigel Announces Reverse Stock Split

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Rigel Announces Reverse Stock Split

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Jun 14, 2024, 3:05 AM EDT - 1 year ago

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Jun 3, 2024, 8:13 AM EDT - 1 year ago

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 23, 2024, 5:00 PM EDT - 1 year ago

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript

May 7, 2024, 9:46 PM EDT - 1 year ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Apr 30, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Apr 4, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Mar 12, 2024, 8:05 AM EDT - 1 year ago

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer